Startup Funding Tracker
Home›People›Peter Svennilson
PS

Peter Svennilson

10% owner at Eikon Therapeutics. Also a director at NGM Bio, Neurona Therapeutics and Carmot Therapeutics.

DirectorPublic companyRoles at 4 startups
Updated Nov 9, 2026·Latest SEC filing Sep 8, 2026·Suggest an edit

About Peter Svennilson

Peter Svennilson is a 10% owner at Eikon Therapeutics.

Form D filings name Peter Svennilson as a director at NGM Bio, Neurona Therapeutics, Carmot Therapeutics and Circle Pharma.

Peter Svennilson reports to the SEC as a director or major shareholder of 13 public companies, including Tenaya Therapeutics (TNYA), Surrozen (SRZN) and RAPT Therapeutics (RAPT).

Peter Svennilson first appears on SEC filings in 2014.

Experience

This experience comes from SEC filings. The years are when the filings name Peter Svennilson in the role, so the role may have started earlier or lasted longer.

Eikon Therapeutics, Inc.
10% owner
2026 · Public company (EIKN)
NGM Bio Holdings, Inc.
Director
2024 – 2026 · South San Francisco, CA
Develops medicines for people with serious diseases through its subsidiary.
Tenaya Therapeutics, Inc.
10% owner
2026 · Public company (TNYA)
Surrozen, Inc.
10% owner
2026 · Public company (SRZN)
Neurona Therapeutics, Inc.
Director
2025 · South San Francisco, CA
RAPT Therapeutics, Inc.
Director and 10% owner
2019 – 2024 · Public company (RAPT)
NGM Biopharmaceuticals Inc.
Director and 10% owner
2019 – 2024 · Public company (NGM)
Carmot Therapeutics Inc.
Director
2020 – 2023 · Berkeley, CA
Oric Pharmaceuticals, Inc.
Director and 10% owner
2020 – 2021 · Public company (ORIC)
eFFECTOR Therapeutics, Inc.
10% owner
2021 · Public company (EFTR)
Circle Pharma, Inc.
Director
2020 – 2021 · South San Francisco, CA
Nurix Therapeutics, Inc.
10% owner
2020 – 2021 · Public company (NRIX)
Revolution Medicines, Inc.
Director and 10% owner
2020 – 2021 · Public company (RVMD)
Constellation Pharmaceuticals Inc.
Director and 10% owner
2018 – 2021 · Public company (CNST)
Gritstone bio, Inc.
Director and 10% owner
2018 – 2019 · Public company (GRTS)
Immune Design Corp.
Director and 10% owner
2014 – 2019 · Public company (IMDZ)
Arcus Biosciences, Inc.
10% owner
2018 · Public company (RCUS)

Key Colleagues at Startups

The people Peter Svennilson works with at each company, as listed on that company's latest Form D.

NGM Bio Holdings, Inc. · Form D/A, Mar 27, 2026
Diana Bockus
Diana Bockus
Chief Executive Officer and director
TK
Tim Kutzkey
Director
RP
Neurona Therapeutics, Inc. · Form D, Apr 4, 2025
TK
Tim Kutzkey
Director
BM
Brad Margus
Director
CN
Cory Nicholas
Executive officer, director and promoter
JS
James Stutz
Chief Financial Officer
RK
Ray Kelleher
Director
EW
LG
Leo Guthart
Director
Carmot Therapeutics Inc. · Form D, Jun 6, 2023
AD
TK
Tim Kutzkey
Director
AT
TG
SD
HT
Heather Turner
Chief Executive Officer and director
Circle Pharma, Inc. · Form D, Jun 29, 2021
ES
Elton Satusky
Executive officer
DE
David Earp
Executive officer and director
WM
Walter Moos
Director
JJ
John Josey
Director
MJ
TS

Sources

  1. SECNGM Bio Holdings, Inc. Form D/A, filed Mar 27, 2026
  2. SECNeurona Therapeutics, Inc. Form D, filed Apr 4, 2025
  3. SECCarmot Therapeutics Inc. Form D, filed Jun 6, 2023
  4. SECCircle Pharma, Inc. Form D, filed Jun 29, 2021
  5. SECForms 3, 4 and 5 filed by Peter Svennilson (SEC filer 1606074)